The Academy of Finland completed the flagship program – Biocenter Oulu group leaders participate in the GeneCellNano project

The GeneCellNano (Gene, Cell and Nano Therapy Competence Cluster for the Treatment of Chronic Diseases)  project is led by Academy Professor Seppo Ylä-Herttuala and the Deputy Director is Professor Seppo Vainio from the University of Oulu, Infotech Oulu and Faculty of Biochemistry and Molecular Medicine. The other participating research group leaders from Oulu are Professors Peppi Karppinen and Lauri Eklund, both from Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine. The University of Helsinki, Aalto University and the Finnish Red Cross Blood Service are also involved. 

GeneCellNano Flagship focuses on the innovation and commercial development of new biological drugs (so-called ATMP products), biomarkers and diagnostics for common chronic diseases. Flagship brings together all Finnish frontline gene therapy, cell therapy and nanotechnology researchers, clinical resources, leading companies and third sector actors. Flagship will create a unique public-private Competence Cluster which has an excellent opportunity to become world leader in this emerging area of biomedicine due to its state-of-the-art innovative basic research, excellent manufacturing technology, pioneering clinical experience and numerous international networks. Flagship aims to significantly increase both domestic and foreign investments in gene, cell and nano therapy, bring new effective therapies to common chronic diseases and create new jobs and companies to biotechnology and drug industry, thus significantly strengthening the development of Finnish economy and society at large.

The flagship program of Academy of Finland supports high-quality research and the resulting broad economic and social impact. The strong commitment of flagship background organizations to the operation and funding of flagships plays a key role in achieving the objectives.

Last updated: 19.11.2020